<DOC>
	<DOCNO>NCT00677391</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety sibutramine vs. placebo combination hypocaloric diet weight-loss overweight obese Malaysian subject .</brief_summary>
	<brief_title>Efficacy Safety Study Sibutramine Overweight Non-Diabetic Malaysian Population</brief_title>
	<detailed_description />
	<mesh_term>Sibutramine</mesh_term>
	<criteria>The subject adequately respond ( i.e. , achieve maintain &gt; 5 % weight loss ) appropriate nonpharmacologic weightreducing regimen ( i.e. , diet exercise ) within 3 month prior Screening . The subject male female 18 65 year age . The subject nutritional obesity BMI &gt; = 27 kg/m2 associate dyslipidemia BMI &gt; = 30 kg/m2 . Dyslipidemia define least one follow three condition : Lowdensity lipoprotein ( LDL ) cholesterol level &gt; 3.4 mmol/L ( &gt; 130 mg/dL ) total cholesterol level &gt; 5.2 mmol/L ( &gt; 200 mg/dL ) triglyceride level &gt; 1.7 mmol/L ( &gt; 150 mg/dL ) . 254 If subject female must either childbearing potential : define postmenopausal least 2 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) contraceptive ( oral parenteral ) 3month period prior Week 0 , vasectomize partner , total abstinence sexual intercourse If subject female , result urine pregnancy test perform Screening Week 0 negative . If subject female , subject breastfeeding . The subject judge general good health base upon result medical history , complete physical examination clinical laboratory test . The subject take overthecounter prescription drug , herbal product weight loss 4 week period prior Screening . The subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , prior undertaking studyspecific procedure History evidence accord 1997 American Diabetic Association ( ADA ) 26criteria type 1 type 2 diabetes mellitus , i.e. , fast plasma glucose level &gt; = 7.0 mmol/L . Inadequately controlled hypertension systolic blood pressure &gt; = 145 mmHg diastolic blood pressure &gt; = 90 mmHg ( average three measurement ) hypertensive subject take &gt; 3 medication control blood pressure . History Gilles de la Tourette 's Syndrome . Use within 4 week prior Week 0 following : Monoamine oxidase inhibitor ( MAOIs ) : use treat depression Parkinson 's disease . Medications regulate neurotransmitter serotonin brain ( SSRIs ) : use treat psychiatric disorder stop smoking . Amino acid : use treat sleep disorder . Certain antimigraine drug ( sumatriptan , dihydroergotamine ) . Opioids ( pentazocine , pethidine , fentanyl , dextromethorphan ) . Organic cause obesity ( e.g. , hypothyroidism ) . History major eat disorder , anorexia nervosa bulimia nervosa . History benign prostatic hyperplasia urinary retention . History neurological disorder seizure . History document psychiatric illness anxiety , depression , bipolar disorder schizophrenia psychotic symptom . History evidence severe renal hepatic impairment . History narrowangle glaucoma . History coronary artery disease , congestive heart failure , peripheral arterial occlusive disease , arrhythmia cerebrovascular disease ( transient ischemic attack stroke ) .13 . History evidence hyperthyroidism . Persistent tachycardia rest , i.e. , heart rate &gt; 100 bpm ( average 3 measurement ) . History primary secondary pulmonary hypertension . Underlying suspected phaeochromocytoma . Known hypersensitivity sibutramine hydrochloride monohydrate component product . Known history drug alcohol abuse . Has previous history use sibutramine . Any medical illness judge investigator may compromise efficacy safety sibutramine . Unlikely cooperate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Obesity</keyword>
</DOC>